A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous
(IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had
previously completed Bonviva study BM16550 (DIVA study; NCT00048074). Patients received
Bonviva either 2 mg IV every 2 months, or 3 mg IV every 3 months. Patients also received
daily supplementation with vitamin D and calcium. The anticipated time on study treatment was
2+ years, and the target sample size was 500+ individuals.